Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis

Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis

Cancer patients are at a very high risk of serious thrombotic events, often fatal. The causes discussed include the detachment of thrombogenic particles from tumor cells or the adverse effects of chemotherapeutic agents. Cytostatic agents can either act directly on their targets or, in the case of a...

Full description

Bibliographic Details
Main Authors: Anne Krüger-Genge, Susanne Köhler, Markus Laube, Vanessa Haileka, Sandy Lemm, Karolina Majchrzak, Sarah Kammerer, Christian Schulz, Joachim Storsberg, Jens Pietzsch, Jan-Heiner Küpper, Friedrich Jung
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cells
Subjects:
cancer
cyclophosphamide
human umbilical vein endothelial cells
HUVEC
liver
cytochrome P450 enzymes (CYP)
Online Access:https://www.mdpi.com/2073-4409/12/15/1965

Internet

https://www.mdpi.com/2073-4409/12/15/1965

Similar Items